While several classes of medications (e.g., sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists), which have demonstrated benefits in slowing the progression of CKD, preventing CVD events, and reducing cardiovascular mortality, have been recommended by the AHA guideline [10], their effects on CKMS of developmental origins have not received as much attention and require further clarification. The gene discussed is GLP1R; the disease is chronic kidney disease.